1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors and analysts on the POLB 001 Oncology Programme on Monday 6 November 2023 at 2:00pm – 3:30pm GMT via the Investor Meet Company platform.
The event will provide an update and greater detail on Poolbeg’s POLB 001 Oncology programme, which is targeting the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments. Severe cases of CRS are life-threatening and may require intensive supportive care, including mechanical ventilation. An effective treatment for CRS has the potential to make these cancer immunotherapies more accessible, while reducing the potentially life-threatening side effects impacting patients and healthcare systems worldwide.
The meeting will be led by Jeremy Skillington, PhD, Chief Executive Officer, and will feature presentations from a number of key opinion leaders and a patient advocate. The meeting will be followed by a Q&A with the guest speakers and Poolbeg’s senior management.
Dr Martin Kaiser, team leader of the Myeloma Molecular Therapy group at the Institute of Cancer Research and Honorary Consultant Haematologist at The Royal Marsden NHS Foundation Trust
Presentation: Current innovations and future outlook in immunotherapy in cancer. The challenges in safely and effectively delivering these therapies to patients.
Bob Munroe, Myeloma Patient Advocate
Presentation: A patients’ perspective: the need for broader access to immunotherapies in cancer, through optimised side effect management.
Professor Brendan Buckley, Scientific Advisory Board Member and Honorary Clinical Professor at University College Cork and University College Dublin
Presentation: POLB 001 as a potential treatment to manage Cytokine Release Syndrome (CRS) associated with onco-immunotherapies and other acute inflammatory conditions.
Registration
The presentation is open to all existing and potential shareholders. Questions can be submitted in advance via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard via:
https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
Investors who already follow Poolbeg on the Investor Meet Company platform will automatically be invited.
